Royalty Pharma PLC $RPRX Shares Acquired by UBS Group AG

UBS Group AG increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 27.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,005,831 shares of the biopharmaceutical company’s stock after purchasing an additional 437,033 shares during the period. UBS Group AG’s holdings in Royalty Pharma were worth $77,505,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in RPRX. Capital International Investors lifted its position in Royalty Pharma by 24.4% during the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock worth $960,064,000 after buying an additional 5,332,074 shares during the period. State Street Corp increased its stake in shares of Royalty Pharma by 0.8% during the 3rd quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock valued at $362,423,000 after acquiring an additional 77,815 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Royalty Pharma by 3.7% during the 3rd quarter. Victory Capital Management Inc. now owns 4,657,407 shares of the biopharmaceutical company’s stock worth $164,313,000 after acquiring an additional 165,727 shares during the period. Northern Trust Corp lifted its holdings in shares of Royalty Pharma by 1.3% during the 3rd quarter. Northern Trust Corp now owns 4,075,239 shares of the biopharmaceutical company’s stock worth $143,774,000 after acquiring an additional 53,389 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Royalty Pharma by 10.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,282,174 shares of the biopharmaceutical company’s stock worth $115,795,000 after acquiring an additional 305,694 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $49.47 on Monday. The stock has a market cap of $28.54 billion, a PE ratio of 36.64, a P/E/G ratio of 3.16 and a beta of 0.40. Royalty Pharma PLC has a fifty-two week low of $31.97 and a fifty-two week high of $50.47. The business has a 50 day moving average price of $47.31 and a two-hundred day moving average price of $42.45. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The company had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. As a group, sell-side analysts predict that Royalty Pharma PLC will post 5.08 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is presently 69.63%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. UBS Group boosted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, April 21st. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. The Goldman Sachs Group reissued a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $50.33.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 274,281 shares of company stock worth $12,422,388. Insiders own 18.84% of the company’s stock.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.